Tricept Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 06-07-2024
- Paid Up Capital ₹ 1.00 M
as on 06-07-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.54 Cr
as on 06-07-2024
- Satisfied Charges ₹ 8.90 M
as on 06-07-2024
- Revenue -97.18%
(FY 2022)
- Profit 100.97%
(FY 2022)
- Ebitda 114.69%
(FY 2022)
- Net Worth 1.22%
(FY 2022)
- Total Assets -20.30%
(FY 2022)
About Tricept Pharmaceuticals
The Corporate was formerly known as Uday Medisales Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.54 Cr. The company has closed loans amounting to ₹8.90 M, as per Ministry of Corporate Affairs (MCA) records.
Ganesan Magesh and Kamal Chand serve as directors at the Company.
- CIN/LLPIN
U51909TN2017PTC118587
- Company No.
118587
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2017
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Tricept Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesan Magesh  | Director | 15-Mar-2019 | Current |
| Kamal Chand | Director | 14-Mar-2022 | Current |
Financial Performance of Tricept Pharmaceuticals.
Tricept Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 97.18% decrease. The company also saw a substantial improvement in profitability, with a 100.97% increase in profit. The company's net worth moved up by a moderate rise of 1.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tricept Pharmaceuticals?
In 2021, Tricept Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Nov 2020 | ₹1.54 Cr | Open |
Indian Bank Creation Date: 04 Jun 2020 | ₹1.20 M | Satisfied |
Indian Bank Creation Date: 09 Apr 2020 | ₹0.70 M | Satisfied |
How Many Employees Work at Tricept Pharmaceuticals?
Unlock and access historical data on people associated with Tricept Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tricept Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tricept Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
